Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 91 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma MOST POPULAR Why people and culture matter in research August 10, 2021 Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... November 14, 2025 Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 Load more HOT NEWS Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in... Mohs Surgery for Skin Cancer: What to Know and What to... In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer EMA Recommends Extension of Indications for Osimertinib
